Recent Updates
Recently added Catalysts

R-pola-mini-CHP

Phase 3

DLBCL | Small Molecules | Oncology |Roche Holding AG|Trials Updated: Sep 19, 2024

R-pola-mini-CHP development status

Highest phase Phase 3
Registered trials 1 across 1 sponsor since Apr 2020

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment300

FDA Designations

No designations recorded

R-pola-mini-CHP clinical trials

R-pola-mini-CHP · 1 trial · 2 indications

Phase 3 1
NCT04332822A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell LymphomaDLBCL
RECRUITING300 Analytics
PHASE3RECRUITING
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
DLBCLUnlock trial analytics

Study Endpoints

Primary Endpoints

Progression-free survival (PFS).
2 years.

Interval between randomization date and date of documented progression, first relapse, or death of any cause

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm A - R-mini-CHOPACTIVE_COMPARATORCycles 1-6, duration 21 days * Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6 * Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6 * Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6 * Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6 * Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6
Arm B - R-pola-mini-CHPEXPERIMENTALCycles 1-6, duration 21 days * Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6 * Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6 * Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6 * Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6 * Polatuzumab vedotin 1.8 mg/kg i.v day 1 cycles 1-6

Interventions

NameTypeDescription
R-pola-mini-CHPDRUG* Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6 * Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6 * Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6 * Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg * Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6
R-mini-CHOPDRUG* Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6 * Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6 * Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6 * Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6 * Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6
Unlock Study Design Details

Eligibility Criteria

Age Range75 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites69

Inclusion Criteria: * Age ≥80 years or frail ≥75 years, according to simplified comprehensive geriatric assessment * Histologically confirmed lymphoma belonging to one of the following subtypes: 1. diffuse large B-cell lymphoma, including transformation from an indolent lymphoma 2. follicular ...

Countries:AustraliaDenmarkFinlandItalyNew ZealandNorwaySweden
Unlock Eligibility Criteria

Frequently asked questions about R-pola-mini-CHP

What is R-pola-mini-CHP?

R-pola-mini-CHP is an investigational combination regimen being studied for diffuse large B cell lymphoma (DLBCL). It pairs polatuzumab vedotin with reduced-intensity CHP chemotherapy, a lower-dose backbone designed for older patients. It is being developed by Roche Holding AG (ticker RHHBY) and is currently in Phase 3 clinical development.

What is R-pola-mini-CHP used for in DLBCL?

R-pola-mini-CHP is being evaluated for the treatment of diffuse large B cell lymphoma (DLBCL), including diffuse large B cell lymphoma, in patients aged 75 years and older. The regimen is intended as a reduced-intensity option for this older population, and it remains investigational rather than approved.

Who makes R-pola-mini-CHP?

Roche Holding AG, which trades under the ticker RHHBY, is the developer of R-pola-mini-CHP. The regimen combines polatuzumab vedotin, a Roche asset, with reduced-intensity CHP chemotherapy. Roche is running the clinical program evaluating this combination in diffuse large B cell lymphoma.

What phase is R-pola-mini-CHP in?

R-pola-mini-CHP is in Phase 3 development. It is investigational and has not been approved by the FDA. The ongoing study is a randomized, active-controlled Phase 3 trial, and no trials of this regimen have been completed to date.

What clinical trials is R-pola-mini-CHP in?

R-pola-mini-CHP is being studied in the Phase 3 trial NCT04332822, titled a randomized, multicenter Phase III trial comparing R-mini-CHOP with R-mini-CHP plus polatuzumab vedotin in patients with diffuse large B cell lymphoma. The trial is recruiting, targets 300 patients, and enrolls participants aged 75 years and older across Australia, Denmark, Finland, Italy, New Zealand, Norway, and Sweden.

Is R-pola-mini-CHP biomarker selected?

Yes. The R-pola-mini-CHP Phase 3 trial NCT04332822 is biomarker selected, meaning enrollment is guided by a biomarker. The study is randomized and active-controlled, comparing the polatuzumab vedotin plus reduced-intensity CHP regimen against R-mini-CHOP in patients with diffuse large B cell lymphoma aged 75 years and older.